New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp

International Journal of Pharmaceutics

Volumn 473, Issue 1-2, 2014, Pages 148-157

  Ruiz, Helga K ^a   Serrano, Dolores R ^a   Dea Ayuela, María Auxiliadora ^b   Bilbao Ramos, Pablo E ^a   Bolás Fernández, Francisco ^a   Torrado, Juan J ^a   Molero, Gloria ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

Author keywords

Amphotericin B; Antifungal activity; Antileishmanial efficacy; Biofilms; Cyclodextrin; Topical formulations

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; DIMETHYL SULFOXIDE; GAMMA CYCLODEXTRIN; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; EXCIPIENT; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA-CYCLODEXTRIN; GEL; SKIN CREAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ANTILEISHMANIAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CREAM; CYBERLINDNERA JADINII; CYTOTOXICITY; DISEASE COURSE; DISK DIFFUSION; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG SOLUBILITY; FUNGICIDAL ACTIVITY; FUNGUS; FUNGUS GROWTH; GEL; IN VITRO STUDY; LEISHMANIA; LEISHMANIA INFANTUM; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; SACCHAROMYCES; SKIN LEISHMANIASIS; SYRIAN HAMSTER; TABLET; TRICHOSPORON; VISCOSITY; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; GROWTH, DEVELOPMENT AND AGING; INFRARED SPECTROSCOPY; MEDICINAL CHEMISTRY; MOUSE; SOLUBILITY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; EXCIPIENTS; FUNGI; GAMMA-CYCLODEXTRINS; GELS; LEISHMANIA; MICE; PARTICLE SIZE; SKIN CREAM; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84904346945     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.07.004     Document Type: Article

References (37)

1. M.A. Al-Fattani, and L.J. Douglas Penetration of Candida biofilms by antifungal agents Antimicrob. Agents Chemother. 48 2004 3291 3297 (Pubitemid 39129321)
2. A. Angelova, C. Ringard-Lefebvre, and A. Baszkin Drug-cyclodextrin association constants determined by surface tension and surface pressure measurements J. Colloid Interface Sci. 212 1999 280 285
3. A. Angelova, C. Ringard-Lefebvre, and A. Baszkin Drug-cyclodextrin association constants determined by surface tension and surface pressure measurements J. Colloid Interface Sci. 212 1999 275 279
4. P.K. Angra, C. Oettinger, S. Balakrishna Pai, and M.J. D'Souza Amphotericin B microspheres: a therapeutic approach to minimize toxicity while maintaining antifungal efficacy J. Microencapsul. 26 2009 580 587
5. K. Cal, and K. Centkowska Use of cyclodextrins in topical formulations: practical aspects Eur. J. Pharm. Biopharm. 68 2008 467 478 (Pubitemid 351318207)
6. R. Challa, A. Ahuja, J. Ali, and R.K. Khar Cyclodextrins in drug delivery: an updated review AAPS PharmSciTech 6 2005 E329 E357
7. M.A. Dea-Ayuela, E. Castillo, M. Gonzalez-Alvarez, C. Vega, M. Rolon, F. Bolas-Fernandez, J. Borras, and M.E. Gonzalez-Rosende In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2- ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide Bioorg. Med. Chem. 17 2009 7449 7456
8. D. Ellis Amphotericin B: spectrum and resistance J. Antimicrob. Chemother. 49 2002 7 10 (Pubitemid 34162651)
9. R. Espada, J.M. Josa, S. Valdespina, M.A. Dea, M.P. Ballesteros, J.M. Alunda, and J.J. Torrado HPLC assay for determination of amphotericin B in biological samples Biomed. Chromatogr. 22 2008 402 407 (Pubitemid 351577704)
10. R. Espada, S. Valdespina, C. Alfonso, G. Rivas, M.P. Ballesteros, and J.J. Torrado Effect of aggregation state on the toxicity of different amphotericin B preparations Int. J. Pharm. 361 2008 64 69
11. European Pharmacopoeia The Council of Europe sixth ed. 2009 European Pharmacopoeia Strasburg 5198 5200
12. R.A. Fernández, M.E. González, J. Fernández, and F.J. Cepeda Fármacos antifúngicos. Situación actual y pautas para su administración Clin. Transl. Oncol. 7 2005 377 388
13. A. Fittler, B. Kocsis, I. Gerlinger, and L. Botz Optimization of bioassay method for the quantitative microbiological determination of amphotericin B Mycoses 53 2010 57 61
14. M. Francois, E. Snoeckx, P. Putteman, F. Wouters, E. De Proost, U. Delaet, J. Peeters, and M.E. Brewster A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole AAPS PharmSci 5 2003 E5
15. D.S. Ghodke, G.M. Chaulang, K.S. Patil, P.D. Nakhat, P.G. Yeole, N.S. Naikwade, and C.S. Magdum Solid state characterization of domperidone: hydroxypropyl-beta-cyclodextrin inclusion complex Indian J. Pharm. Sci. 72 2010 245 249
16. T. Higuchi, and K. Connors Phase-solubility techniques Adv. Anal. Chem. Instr. 1965 217 310
17. P.L.T. Jansook CDs as solubilizers: effects of excipients and competing drugs Int. J. Pharm. 379 2009 32 40
18. P. Jansook, S.V. Kurkov, and T. Loftsson Cyclodextrins as solubilizers: formation of complex aggregates J. Pharm. Sci. 99 2010 719 729
19. M. Kajtár, M. Vikmon, E. Morlin, and J. Szejtli Aggregation of amphotericin B in the presence of gamma-cyclodextrin Biopolymers 28 1989 1585 1596
20. Y.T. Kim, B.K. Shin, V.K. Garripelli, J.K. Kim, E. Davaa, S. Jo, and J.S. Park A thermosensitive vaginal gel formulation with HPγCD for the pH-dependent release and solubilization of amphotericin B Eur. J. Pharm. Sci. 41 2010 399 406
21. T. Loftsson, and M.E. Brewster Cyclodextrins as functional excipients: methods to enhance complexation efficiency J. Pharm. Sci. 101 2012 3019 3032
22. T. Loftsson, D. Hreinsdottir, and M. Masson Evaluation of cyclodextrin solubilization of drugs Int. J. Pharm. 302 2005 18 28 (Pubitemid 41244817)
23. C.A. Lopez, A.H. de Vries, and S.J. Marrink Molecular mechanism of cyclodextrin mediated cholesterol extraction PLoS Comput. Biol. 7 2011 e1002020
24. A. Martinez, T. Carreon, E. Iniguez, A. Anzellotti, A. Sanchez, M. Tyan, A. Sattler, L. Herrera, R.A. Maldonado, and R.A. Sanchez-Delgado Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells J. Med. Chem. 55 2012 3867 3877
25. B. Prakash, S. Suresh, C. Narendra, and Balasangameshwer Physicochemical characterization of β-cyclodextrin and hydroxy ethyl β-cyclodextrin complexes of rifampicin Ars Pharm. 47 2006 37 59 (Pubitemid 44651468)
26. I. Pujol, F.J. Pastor, M. dos Santos Lazera, and J. Guarro Evaluation of the Neo-Sensitabs diffusion method for determining the antifungal susceptibilities of Cryptococcus gattii isolates, using three different agar media Rev. Iberoam. Micol. 25 2008 215 220
27. I. Puskas, and F. Csempesz Influence of cyclodextrins on the physical stability of DPPC-liposomes Colloids Surf. B: Biointerfaces 58 2007 218 224 (Pubitemid 46921459)
28. N. Rajagopalan, S.C. Chen, and W.S. Chow A study of the inclusion complex of amphotericin-B with γ-cyclodextrin Int. J. Pharm. 29 1986 161 168 (Pubitemid 16102007)
29. R. Rowe, P. Sheskey, and M. Quinn Handbook of Pharmaceutical Excipients 2009 Pharmaceutical Press and American Pharmacist Association London and Grayslake 888
30. Y.H. Samaranayake, J. Ye, J.Y. Yau, B.P. Cheung, and L.P. Samaranayake In vitro method to study antifungal perfusion in Candida biofilms J. Clin. Microbiol. 43 2005 818 825 (Pubitemid 40256040)
31. J.A. Sánchez-Brunete, M.A. Dea, S. Rama, F. Bolás, J.M. Alunda, R. Raposo, M.T. Méndez, S. Torrado-Santiago, and J.J. Torrado Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres Antimicrob. Agents Chemother. 48 2004 3246 3252 (Pubitemid 39129314)
32. D.R. Serrano, H.K. Ruiz-Saldana, G. Molero, M.P. Ballesteros, and J.J. Torrado A novel formulation of solubilised amphotericin B designed for ophthalmic use Int. J. Pharm. 437 2012 80 82
33. E. Sobarzo-Sanchez, P. Bilbao-Ramos, M. Dea-Ayuela, H. Gonzalez-Diaz, M. Yanez, E. Uriarte, L. Santana, V. Martinez-Sernandez, F. Bolas-Fernandez, and F.M. Ubeira Synthetic oxoisoaporphine alkaloids: in vitro, in vivo and in silico assessment of antileishmanial activities PLoS One 8 2013 e77560
34. J. Szejtli Utilization of cyclodextrins in industrial products and processes J. Mater. Chem. 7 1997 575 587 (Pubitemid 127730026)
35. J. Szejtli Introduction and general overview of cyclodextrin chemistry Chem. Rev. 98 1998 1743 1754
36. J.J. Torrado, R. Espada, M.P. Ballesteros, and S. Torrado-Santiago Amphotericin B formulations and drug targeting J. Pharm. Sci. 97 2008 2405 2425
37. K. Uekama Design and evaluation of cyclodextrin-based drug formulation Chem. Pharm. Bull. (Tokyo) 52 2004 900 915 (Pubitemid 41701863)